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To the editor 
Sodium glucose cotransporter-2 inhibitors (SGLT-2i) are increasingly used in the management of type 2 diabetes 
(T2DM) due to their effective glucose-lowering and secondary benefits of weight loss, blood pressure reduction and 
low risk of hypoglycaemia.(1) In 2015, the US food and drug administration (FDA) reported 21 cases of diabetic 
ketoacidosis (DKA) associated with SGLT-2i use via the FDA Adverse Event Reporting System (FAERS). 102 events 
were subsequently identified by the European Medicines Agency (EMA) from EudraVigilance.(2, 3) Since then several 
case reports have been published (4-15) and DKA is now a recognised rare side-effect of SGLT-2i (1 in 1000). (16)  
Here we report eight cases of DKA in association with SGLT-2i use; 5 with dapagliflozin, 2 with canagliflozin and 1 
with empagliflozin (see table-1 in addendum). These occurred in a catchment population of about 500,000 in the 
United Kingdom over a period of one year with a background prevalence of 7% for type 2 diabetes in adults and 8.4% 
patients being treated with SGLT-2i.(17)  All cases had previously been labelled as having T2DM, with a mean duration 
of diabetes of 16.75 (range 9-30) years. They were commenced on SGLT-2i for poorly controlled glycaemia (mean 
HbA1c = 99 ± 28 mmol/mol [11.2 ± 4.7 %]) on a background of obesity (mean BMI = 34.31 kg/m2).   
All cases had been on SGLT-2i for approximately 3 months before presenting with DKA, with the exception of # 1 
who developed DKA after 13 days treatment with dapagliflozin; in this case the patient had erroneously stopped all 
her insulin (100 units daily dose) when dapagliflozin was initiated. Seven patients were over the age of 50 years, the 
exception being #5, a 37 year old woman with previous gestational diabetes which had progressed to T2DM (BMI 
35.1 kg/m2; HbA1c 133 mmol/mol [14.3%]). She developed severe DKA associated with dental sepsis after being 
switched to dapagliflozin monotherapy from the triple combination of metformin, exenatide and insulin (96 units 
daily dose).  
The only case not to be initially treated with insulin was a 70 year old woman (# 6) with T2DM for 30 years who was 
managed on metformin and sitagliptin. She developed DKA as an in-patient following an extended period of fasting 
whilst awaiting surgical drainage of bilateral axillary abscesses.  
Three of the subjects subsequently tested positive for anti-GAD antibodies, suggesting a diagnosis of latent 
autoimmune diabetes in adults (LADA). In two of these cases (# 3 & 7) insulin had been initiated in the same year as 
their diabetes diagnosis and one (case # 2) had experienced previous episodes of DKA; these clinical features are 
consistent with LADA, for which SGLT2i are not currently licenced.  
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One case (#4) had previous history of idiopathic pancreatitis and gastroparesis who tolerated SGLT-2i for more than 
3 years before presenting with DKA precipitated by vomiting with flare up of gastroparesis. 
None of the DKA cases presented with normal or subnormal blood glucose (<11 mmol/L; 200 mg/dL) which has been 
reported in around 60% of case reports (so-called ‘euglycaemic DKA’) and six presented with a blood glucose higher 
than 20 mmol/L (360 mg/dL). Two cases (case # 4 & 8) were detected before developing overt DKA (pH 7.32 and 
7.31) but had raised capillary ketones (7.3 and 2.2 mmol/L). In all cases DKA resolved within 24 hours with a standard 
protocol using intravenous insulin and fluids and intensive care was not required.  A recognised precipitant of DKA 
was identified in all cases (see table-2 in addendum) and the SGLT-2i was with-held with no re-challenge.  
The exact mechanism of DKA with SGLT-2i use is incompletely understood but mild asymptomatic ketonaemia is an 
effect of SGLT-2i. This may be due to increased fatty acid utilization with SGLT-2i resulting from a reduction of the 
insulin to glucagon ratio and also increased urinary ketone absorption.(18-20) We recommend caution when 
prescribing SGLT-2i for middle-aged and elderly patients on high dosages of insulin and rapid reduction of insulin 
should be discouraged. ‘Sick day rules’ should be applied with the temporary cessation of SGLT-2i therapy during any 
episode of vomiting and reduced oral intake. The drug regulatory bodies and expert societies suggest not to restart 
SGLT-2i in a patient who experiences an unprovoked episode of DKA.(16, 21, 22)  The presence of conventional risk 
factors  for DKA along with SGLT-2i usage should alert clinicians to discontinue this drug temporarily to avoid this 
preventable but life-threatening complication. Patient education and provision of alert cards is good clinical practice 
when prescribing this drug class. 
 
 
 
 
 
 
 
 
Table-1-A and 1-B: Eight cases of DKA associated with SGLT-2i use presenting locally (please see addendum) 
Table-2: List of recognised risk factors for diabetic ketoacidosis (please see addendum) 
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Table:1-A; Eight cases of DKA associated with SGLT-2i use presenting locally (Anti-GAD antibody negative) 
No 
(Age) 
Age at diagnosis 
and duration of 
diabetes  
Anti-GAD 
Antibodies 
† 
SGLT-2i  
(Duration of 
use) ‡ 
BMI 
(kg/m2) 
Prior 
Insulin use 
(Type) 
Insulin 
Regime 
(Total daily 
dose) § 
Insulin dose 
reduced 
(Amount) 
Concomit
ant drugs 
Prior 
HbA1c 
mmol/mol 
Potential 
precipitant for 
DKA ¶ 
pH HCO3 
mmol/L 
Glucose 
mmol/L 
Ketones 
mmol/L 
Case 1 
 (59yr) 
42 & 17yrs Negative DAPA (13 
days) 
34.2 Yes 
(Humalog 
Mix 50) 
 Biphasic 
insulin BD 
(100 units)  
Yes 
(100 units) 
Metformi
n, 
Liraglutid
e 
128 Stopped insulin 
(100units) 
7.16 15 41 8 
Case 4  
 (52yr) 
37 & 15yrs 
  
Negative DAPA (1145 
days) 
28.4 Yes 
(Degludec & 
Novorapid) 
Basal bolus 
regime 
(134 units)  
No 
(0 units) 
Metformi
n  
94 Gastroparesis 7.32 15.8 32.3 7.3 
Case 5  
 (37yr) 
27 & 10yrs Negative DAPA (170 
days) 
35.1 Yes 
(Humulin 
M3) 
Biphasic 
insulin BD 
(96 units)  
Yes  
(96 units) 
Metformi
n, 
Exenatide
,  
Gliclazide 
(stopped 
all)  
133 Dental sepsis/ 
with-held insulin 
6.97 5 31.8 3.9 
Case 6 
 (70yr) 
40 & 30yrs Negative  CANA (121 
days) 
39.4 No  Not 
applicable 
Not 
applicable 
Metformi
n, 
Sitagliptin 
86 Prolonged pre-
operative fasting 
7.29 17.9 35.4 3.1 
Case 8  
(59yr) 
50 & 9yrs  Negative  EMPA (90 
days) 
42.6 Yes 
(Novomix 
30) 
Biphasic 
insulin BD 
(112 units) 
Yes  
(60 units) 
Metformi
n, 
Gliclazide, 
Liraglutid
e 
80 SAIO/ 
Right 
hemicolectomy 
(post-op) 
7.31 17.1 14.0 2.2 
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Table 1-B; Eight cases of DKA associated with SGLT-2i use presenting locally (Anti-GAD antibody positive) 
No 
(Age) 
Age at diagnosis 
and duration of 
diabetes  
Anti-GAD 
Antibodies † 
SGLT-2i  
(Duration 
of use) ‡ 
BMI 
(kg/m2) 
Prior  
Insulin 
Insulin 
Regime 
(Total daily 
dose) § 
Insulin 
dose 
reduction 
Concomit
ant drugs 
Prior HbA1c 
mmol/mol 
Potential 
precipitant for 
DKA ¶ 
pH HCO3 
mmol/L 
Glucose 
mmol/L 
Ketones 
mmol/L 
Case 2  
 (59yr) 
45 & 14yrs Positive 
(295U/ml) 
DAPA (80 
days) 
34.3 Yes 
(Levemir & 
Novorapid) 
Basal bolus 
insulin 
MDI (34 
units) 
Uncertain Metformi
n 
119 Diarrhoea 7.21 13.7 27.8 5.4 
Case 3 
 (51yr) 
42 & 9yrs  Strongly 
positive 
(6350U/ml) 
DAPA (87 
days) 
30 Yes 
(Humalog 
Mix 50) 
Biphasic 
insulin TDS 
(42 units) 
Yes 
(but dose 
unknown) 
Metformi
n, 
Liraglutid
e 
80 Vomiting 7.09 8.3 19.9 6.6 
Case 7 
(64yr) 
34 & 30yrs Lightly positive 
(15U/ml) 
CANA (90 
days) 
30.5 Yes 
(Novorapid 
& Lantus) 
Basal bolus 
MDI 
(unknown) 
Yes 
(stopped 
all) 
None  72 Vomiting/ 
gastroenteritis 
7.15 9.8 36.2 7.4 
 
† Anti-GAD antibodies = Anti Glutamic acid decarboxylase antibodies 
‡ DAPA = Dapagliflozin, CANA = Canagliflozin, EMPA = Empagliflozin.   
§ BD = Twice daily, TDS = Thrice daily, MDI = Multiple daily injections 
¶ SAIO = Subacute intestinal obstruction 
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Table; 2 List of recognised risk factors for diabetic ketoacidosis 
 
● Undiagnosed T1DM/LADA (uncertain history of onset of diabetes) 
● Massive reduction in insulin dosages 
● Post-operative state  
● Starvation/extended fasting/Low carbohydrate intake  
● Gastroparesis   
● Pancreatic insufficiency   
● Acute stress/viral illness/severe sepsis 
● Acute coronary syndrome 
● Alcohol consumption 
● Moderate exercise without enough carbohydrate intake  
● Clinicians’ misjudgement 
● Elderly patients (>65 years) 
● Long standing history of diabetes (>30 years) 
 
 
